Somatostatinrezeptor-PET

Zusammenfassung Die SSTR-PET/CT ist Goldstandard in der Bildgebung von G1-/G2-NET. Sie hat eine signifikant höhere diagnostische Genauigkeit als die CT, erlaubt eine zuverlässige Primär- und Rezidivdiagnostik, und hat dadurch einen signifikanten Einfluss auf das therapeutische Management von Patienten mit NET. Eine Therapie mit kalten SSA muss für die SSTR-PET nicht unterbrochen werden. Die SSTR-PET/MRT kann sicherlich noch nicht als Standard angesehen werden, kann aber insbesondere bei Leber- und Knochenmetastasen hilfreich sein. Neue Entwicklungen in Richtung antagonistische SSA sind vielversprechend.

[1]  H. Amthauer,et al.  Somatostatinrezeptor-PET/CT , 2018, Nuklearmedizin.

[2]  G. Karanikas,et al.  Whole-Body 68Ga-DOTANOC PET/MRI Versus 68Ga-DOTANOC PET/CT in Patients With Neuroendocrine Tumors , 2017, Clinical nuclear medicine.

[3]  W. Oyen,et al.  Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  Gerald Antoch,et al.  Evaluation of 68Ga-DOTATOC PET/MRI for whole-body staging of neuroendocrine tumours in comparison with 68Ga-DOTATOC PET/CT , 2017, European Radiology.

[5]  V. Ambrosini,et al.  The Impact of Somatostatin Receptor–Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis , 2017, The Journal of Nuclear Medicine.

[6]  P. Herscovitch,et al.  Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  F. Beuschlein,et al.  Neuroendocrine tumor recurrence: diagnosis with 68Ga-DOTATATE PET/CT. , 2013, Radiology.

[8]  G. Schmidt,et al.  The Role of 68Ga-DOTATATE PET/CT in Suspected Neuroendocrine Tumors , 2012, The Journal of Nuclear Medicine.

[9]  A. Scarpa,et al.  Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. , 2012, European journal of cancer.

[10]  E. Demirci,et al.  Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  C. Boy,et al.  68Ga-DOTATOC Versus 68Ga-DOTATATE PET/CT in Functional Imaging of Neuroendocrine Tumors , 2011, The Journal of Nuclear Medicine.

[12]  P. Cumming,et al.  Treatment with Octreotide Does Not Reduce Tumor Uptake of 68Ga-DOTATATE as Measured by PET/CT in Patients with Neuroendocrine Tumors , 2011, The Journal of Nuclear Medicine.

[13]  H. Amthauer,et al.  68Ga-DOTATOC PET/CT of Neuroendocrine Tumors: Spotlight on the CT Phases of a Triple-Phase Protocol , 2011, The Journal of Nuclear Medicine.

[14]  P. Cumming,et al.  68Ga-DOTATATE PET/CT for the Early Prediction of Response to Somatostatin Receptor–Mediated Radionuclide Therapy in Patients with Well-Differentiated Neuroendocrine Tumors , 2010, The Journal of Nuclear Medicine.

[15]  I. Kayani,et al.  The Role of 68Ga-DOTATATE PET in Patients with Neuroendocrine Tumors and Negative or Equivocal Findings on 111In-DTPA-Octreotide Scintigraphy , 2010, Journal of Nuclear Medicine.

[16]  R. Bale,et al.  68Ga-DOTA-Tyr3-Octreotide PET for Assessing Response to Somatostatin-Receptor–Mediated Radionuclide Therapy , 2009, Journal of Nuclear Medicine.

[17]  B. Skogseid,et al.  Elevated Plasma Chromogranin A Is the First Indication of Recurrence in Radically Operated Midgut Carcinoid Tumors , 2009, Neuroendocrinology.

[18]  Manal M. Hassan,et al.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  E. Krenning,et al.  Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  O. Schillaci Somatostatin Receptor Imaging in Patients with Neuroendocrine Tumors: Not Only SPECT? , 2007, Journal of Nuclear Medicine.

[21]  Judit Erchegyi,et al.  Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors , 2006, Proceedings of the National Academy of Sciences.

[22]  I. Modlin,et al.  A 5‐decade analysis of 13,715 carcinoid tumors , 2003, Cancer.

[23]  A. Haug,et al.  Impact of 68Ga-DOTATATE PET/CT on the Surgical Management of Primary Neuroendocrine Tumors of the Pancreas or Ileum , 2014, Annals of Surgical Oncology.

[24]  A. Haug,et al.  Treatment with octreotide in patients with well-differentiated neuroendocrine tumors of the ileum: prognostic stratification with Ga-68-DOTA-TATE positron emission tomography. , 2014, Molecular imaging.

[25]  V. Ambrosini,et al.  Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68Ga-DOTA-NOC receptor PET/CT , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  R. Bale,et al.  Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT , 2007 .